Eleven patients with Paget's disease treated with sodium etidronate 20 mg/kg/day for two and four weeks showed significant reductions in plasma alkaline phosphatase activity and urinary hydroxyproline excretion, both of which are biochemical markers of bone turnover. After four weeks of treatment, however, histological examination of iliac crest biopsy samples showed that despite a rapid reduction in bone resorption there was an appreciable mineralisation defect; even after only two weeks' treatment the abnormalities in bone formation persisted for up to 10 weeks.
Introduction
When sodium etidronate (EHDP) was first used in Paget's disease doses of 10-20 mg/kg/day for six months reduced the plasma alkaline phosphatase activity and urinary hydroxyproline excretion, both of which are biochemical markers of bone turnover. 2 This regimen, however, resulted in a mineralisation defect and an increased prevalence of fractures, particularly with the higher doses,'34 indicating that high doses for long periods must be used with caution. Reducing the dose does not circumvent these problems as it results not only in decreased efficacy2 but also in abnormalities of mineralisation, described as "focal osteomalacia."I Because of the satisfactory biochemical response obtained within three months of treatment with sodium etidronate a dose of 20 mg/kg/day for shorter periods has been suggested. 6 We aimed to determine the effect of such high doses on biochemistry and bone histology when given for short periods (two and four weeks).
Methods
We studied 11 patients (six men, five women) aged 48-74 with symptomatic Paget's disease. All had radiographic evidence of the disease and raised plasma alkaline phosphatase activity. Three Table I shows the biochemical values in the six patients given four weeks' treatment. Plasma phosphate concentration rose during treatment but had fallen at three and six months. Plasma alkaline phosphatase activity had fallen at the end of treatment, but the maximum effect was noted at three months. The ratio of urinary hydroxyproline to creatinine had fallen at the end of treatment but had started to rise at three months. Table II shows the results of histological examination of bone in the six patients. The proportion of resorbing surfaces, the proportion of forming surfaces bearing a calcification front, and the trabecular calcification rate fell while the proportion of forming surfaces and the seam width increased. Tables III and IV show the findings in the five patients treated for two weeks. Plasma phosphate concentration increased during treatment but had returned to the pretreatment value by three months. Plasma alkaline phosphatase activity did not decrease until one month after the start of treatment and then continued to fall. The ratio of urinary hydroxyproline to creatinine fell with treatment. Histological examination of a bone biopsy specimen taken immediately after treatment in one case (case 7) showed a mineralisation defect (table IV) ; biopsy specimens obtained after 10 weeks in three cases did not show such a defect, although bone resorption was increased in two (cases 8 and 9).
Discussion
Sodium etidronate 20 mg/kg/day produces a clinical, biochemical, and histological response in patients with Paget's disease when given for six months. 12 Our study showed that it also produces a beneficial response when given for two to four weeks. The biochemical markers of bone resorption, plasma alkaline phosphatase activity and the urinary hydroxyproline:creatinine ratio, decreased during the course of treatment and remained suppressed for three months. The change in plasma alkaline phosphatase activity lagged behind that in the hydroxyproline:creatinine ratio, with a maximal response at three months. The plasma phosphate concentration increased after two weeks' treatment owing to increased tubular reabsorption of phosphate," a reliable signal that the drug had been absorbed. The bone histology in the patients from whom biopsy specimens were taken on two occasions was consistent with the biochemical response, showing a fall in resorbing surfaces after treatment for one month.
The biopsy specimens taken after one month's treatment showed that a pronounced mineralisation defect had developed. Histo-morphometry showed an increase in forming surfaces, a reduction in the extent of surfaces bearing a calcification front, and a reduced rate of trabecular calcification. Osteomalacia, as defined by both an increase in osteoid surfaces and a reduction in calcification fronts, was present in five out of six patients. Previous studies after three to six months' treatment showed similar histological changes.2 3 Even after only two weeks' treatment we found evidence of a mineralisation defect, which confirms recent findings.'2 In our study biopsy more than 10 weeks after two weeks' treatment showed no impairment of bone formation. Thus the mineralisation defect was probably not permanent and resolved spontaneously, as others have shown. 2 One study showed that the mineralisation defect persisted for up to nine months after the end of treatment,' but treatment was for 29 weeks, suggesting that persistence of the defect depends on the dose.
Whether repeated short courses of sodium etidronate 20 mg/kg! day produces less impairment of mineralisation than protracted treatment remains to be established. One study showed that symptoms and biochemical variables were controlled with sodium etidronate 20 mg/kg/day for one month out of every four over two years. 13Bone histology, however, was not examined. Another study suggested that the biochemical activity of the disease remains Conversion: SI to traditional units-Calcium: 1 mmol/l 4 mg/100 ml. Phosphate: 1 mmol/l 31 mg/100 ml. Hydroxyproline:creaiinine: 1 imol/mmol-1 2 mg/g. suppressed after only one month's treatment.'2 We, however, found that the inhibition of bone resorptionis temporary and that control of the disease needs repeated courses of treatment. The precise mechanism causing the mineralisation defect is not known but was unrelated to changes in 1,25(OH)2 vitamin D in this study. Possible side effects of sodium etidronate include interference with alkaline phosphatase activity, reduced synthesis of proteoglycans, and a toxic effect on bone cells. 14 In conclusion, sodium etidronate 20 mg/kg/day results in a biochemical improvement in Paget's disease when given for as short a period as two to four weeks, but it produces a mineralisation defect and the effect on bone resorption is not permanent. Although the defect in mineralisation spontaneously corrects when treatment is stopped we doubt whether any manipulation ofthe dose or duration of tieatment can dissociate the drug's beneficial effects on resorption from its adverse effects on mineralisation. It is not, therefore, ideal for long term management of patients with Paget's disease.
Introduction
In 1965 Wilson showed that plasma and urinary thiocyanate concentrations were lower in a group of smokers with Leber's hereditary optic neuropathy than in a control group without this neuropathy.' This and the finding of raised plasma cyanocobalamin concentrations in these patients' led to the hypothesis that there is an inborn error in cyanide detoxication in patients with Leber's hereditary optic neuropathy." Another hypothesis is that Leber's hereditary optic neuropathy is a hereditary vascular neuroretinopathy. 4 The main detoxication route for cyanide is the enzymic transfer of sulphur from thiosulphate (or mercaptopyruvate) to cyanide to form thiocyanate. Wilson found no difference in the activity of thiosulphate sulphurtransferase (rhodanese; EC 2.8.1.1) in liver samples taken at necropsy of two patients who had had Leber's hereditary optic neuropathy compared with samples from controls. ' In 1981, however, Cagianut et al reported reduced activity of liver rhodanese in two patients with Leber's hereditary optic neuropathy compared with living and dead controls. 5 Rhodanese is an intramitochondrial enzyme and therefore may be found in most tissues; it occurs in large quantities in the liver and kidneys. For ethical and practical purposes rectal mucosa was chosen as the -source of specimens for our enzyme assays. We compared the activity of rectal mucosa rhodanese in subjects with Leber's hereditary optic neuropathy with that in control subjects. In addition, rhodanese activity was measured in liver and rectal mucosa obtained at necropsy from controls.
Patients and methods
Ten white men with Leber's hereditary optic neuropathy from nine different families living in southern England were studied. All had optic atrophy that was inherited matroclinically and fulfilled the criteria of the diagnosis of Leber's hereditary optic neuropathy described by Lundsgaard6 -namely, a predominantly male affection with acute or subacute bilateral visual loss with central scotomas. At least one subject on the maternal side of each pedigree had been similarly affected. Control specimens were obtained from 12 white patients (seven men, five women) undergoing investigations for various bowel disorders such as carcinoma, colitis, and idiopathic diarrhoea ("diseased" controls) and from 20 white patients (17 men, three women) undergoing routine colonoscopy for colonic polyps ("healthy" controls). Three doctor volunteers also acted as "healthy" controls. Rectal
